Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D15BZU
|
|||
Drug Name |
Brilaroxazine
|
|||
Synonyms |
Brilaroxazine; 1239729-06-6; X8L60BA01I; UNII-X8L60BA01I; 6-(4-(4-(2,3-Dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo(b)(1,4)oxazin-3(4H)-one; RP-5063; 2H-1,4-Benzoxazin-3(4H)-one, 6-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-; 6-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2H-benzo(b)(1,4)oxazin-3(4H)-one; 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo[b][1,4]oxazin-3(4h)-one; 2H-1,4-Benzoxazin-3(4H)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-; 6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one; Brilaroxazin; BRILAROXAZINE [INN]; BRILAROXAZINE [WHO-DD]; SCHEMBL3404085; CHEMBL5095172; BDBM312188; DTXSID001136921; AKOS040741455; DB09226; MS-28159; US9604944, 15b (Example 14); HY-109112; CS-0077721; 6-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-2H-1,4-benzoxazin-3(4H)-one; 2036070-48-9
Click to Show/Hide
|
|||
Drug Type |
Small molecule
|
|||
Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 1 | [1] | |
Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Phase 1 | [1] | ||
Company |
Reviva Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H25Cl2N3O3
|
|||
Canonical SMILES |
C1CN(CCN1CCCCOC2=CC3=C(C=C2)OCC(=O)N3)C4=C(C(=CC=C4)Cl)Cl
|
|||
InChI |
InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28)
|
|||
InChIKey |
PMKMNTBZJOXTJW-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Serotoninnorepinephrinedopamine reuptake (SNDR) | Target Info | Agonist | [1] |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of Reviva Pharmaceuticals |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.